PERITONEAL AND PLEURAL TUBERCULOSIS SECONDARY TO ANTI-TNF THERAPY - CASE REPORT

The discovery of drugs that block the action of tumor necrosis factor, the called anti-TNF alpha, revolutionized the treatment of many inflammatory diseases; however, they have potentially serious side effects. One of them is the reactivation of latent tuberculosis, which in the presence of an immunosuppressive condition commonly presents as extrapulmonary forms. The authors present a case of peritoneal and pleural tuberculosis secondary to therapy with an immunobiological anti-TNF alpha (Adalimumab).